Mozaffari S - Search Results

1

Managing Big Data for Addressing Research Questions in a Collaborative Project on Automated Driving Impact Assessment.

Bellotti F, Osman N, Arnold EH, Mozaffari S, Innamaa S, Louw T, Torrao G, Weber H, Hiller J, De Gloria A, Dianati M, Berta R. Bellotti F, et al. Among authors: mozaffari s. Sensors (Basel). 2020 Nov 27;20(23):6773. doi: 10.3390/s20236773. Sensors (Basel). 2020. PMID: 33260831 Free PMC article.

2

Exploiting Big Data for Experiment Reporting: The Hi-Drive Collaborative Research Project Case.

Capello A, Fresta M, Bellotti F, Haghighi H, Hiller J, Mozaffari S, Berta R. Capello A, et al. Among authors: mozaffari s. Sensors (Basel). 2023 Sep 13;23(18):7866. doi: 10.3390/s23187866. Sensors (Basel). 2023. PMID: 37765923 Free PMC article.

3

Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new?

Mozaffari S, Nikfar S, Abdollahi M. Mozaffari S, et al. Expert Opin Drug Metab Toxicol. 2024 Apr 26. doi: 10.1080/17425255.2024.2348488. Online ahead of print. Expert Opin Drug Metab Toxicol. 2024. PMID: 38668452 Review.

4

Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.

Mars N, Kerminen S, Tamlander M, Pirinen M, Jakkula E, Aaltonen K, Meretoja T, Heinävaara S, Widén E, Ripatti S; FinnGen. Mars N, et al. J Clin Oncol. 2024 May 1;42(13):1477-1487. doi: 10.1200/JCO.23.00295. Epub 2024 Feb 29. J Clin Oncol. 2024. PMID: 38422475

5

Drugs of the future for diarrhea-predominant irritable bowel syndrome: an overview of current investigational drugs.

Mozaffari S, Nikfar S, Abdollahi M. Mozaffari S, et al. Expert Opin Investig Drugs. 2024 Mar;33(3):219-228. doi: 10.1080/13543784.2024.2320703. Epub 2024 Feb 23. Expert Opin Investig Drugs. 2024. PMID: 38366822 Review.

6

Quantum oscillations evidence for topological bands in kagome metal ScV₆Sn₆.

Zheng G, Zhu Y, Mozaffari S, Mao N, Chen KW, Jenkins K, Zhang D, Chan A, Arachchige HWS, Madhogaria RP, Cothrine M, Meier WR, Zhang Y, Mandrus D, Li L. Zheng G, et al. Among authors: mozaffari s. J Phys Condens Matter. 2024 Feb 26;36(21). doi: 10.1088/1361-648X/ad2803. J Phys Condens Matter. 2024. PMID: 38335546

7

Sex-specific genetic risks for adverse outcomes after coronary revascularization procedures.

Nurkkala JM, Aittokallio J; FinnGen; Kauko A, Niiranen T. Nurkkala JM, et al. Interdiscip Cardiovasc Thorac Surg. 2024 Jan 2;38(1):ivae006. doi: 10.1093/icvts/ivae006. Interdiscip Cardiovasc Thorac Surg. 2024. PMID: 38216540 Free PMC article.

8

Human-Robot Interaction Using Learning from Demonstrations and a Wearable Glove with Multiple Sensors.

Singh R, Mozaffari S, Akhshik M, Ahamed MJ, Rondeau-Gagné S, Alirezaee S. Singh R, et al. Among authors: mozaffari s. Sensors (Basel). 2023 Dec 12;23(24):9780. doi: 10.3390/s23249780. Sensors (Basel). 2023. PMID: 38139627 Free PMC article.

9

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061372 Free article. Clinical Trial.

10

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.

EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061371 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

151 results

Search Page